Russia COVID-19 Vaccine 'Sputnik V' DS Dedicated Production
Huons Global-Led Consortium Participation... Contributing to Russia COVID Vaccine Distribution
Utilizing Smart Digital Biofactory Started in March, Production Scheduled from August
[Asia Economy Reporter Hyungsoo Park] Prestige BioPharma, a pharmaceutical company specializing in antibody drug development, announced on the 16th that it will participate as a consortium member in the technology transfer contract for the production of the Russian COVID-19 vaccine, Sputnik V.
Sputnik V is a COVID-19 preventive vaccine independently developed by the Gamaleya National Research Center for Epidemiology and Microbiology under the Russian Ministry of Health. The contract will proceed in the form of participation as the dedicated supplier of the drug substance (Drug Substance, DS) in the production contract consortium led by Huons Global Co., Ltd.
Prestige BioPharma's vaccine center, which began construction in March, is being built with the goal of proactive response to COVID-19 and future infectious diseases. The vaccine center is scheduled for trial operation in August this year. From September, it aims to start full-scale production with a batch size of 2000 liters, the world's first of its scale, and is promoting technology transfer and related preparations.
In particular, it is expected that mass vaccine production will be possible in a short time by utilizing the ALITA Smart Biofactory Single-Use system, a patented technology of its affiliate Prestige BioLogics. The ALITA Smart Biofactory is the world's first process operation system based on digital artificial intelligence, a futuristic engineering system that minimizes real-time process deviations and human errors while improving production efficiency.
Park Soyeon, CEO of Prestige BioPharma, said, “We are pleased and feel a heavy sense of responsibility to participate in the production and development cooperation of Sputnik V, the world's first COVID-19 preventive vaccine to be approved.”
She added, “Starting with this vaccine production, we aim to directly develop vaccines that can respond to infectious diseases that may emerge in the future.” She also emphasized, “We are proud to fulfill our social responsibility as a company possessing related technologies for vaccine production to eradicate COVID-19, a wish shared by people worldwide.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
